Published in BMJ on November 06, 2009
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes (2011) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Platelet aggregation pathway. Pharmacogenet Genomics (2011) 1.04
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One (2013) 1.03
Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc (2013) 1.03
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol (2011) 0.98
Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One (2014) 0.98
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Cardiovascular Disease in Women: Clinical Perspectives. Circ Res (2016) 0.92
The missing men: high risk of disease in men of Mexican origin. Am J Mens Health (2010) 0.90
Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis (2012) 0.90
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One (2012) 0.86
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol (2010) 0.86
Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes (2012) 0.85
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med (2011) 0.83
Aspirin: pharmacology and clinical applications. Thrombosis (2011) 0.83
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol (2016) 0.82
Diabetes as an independent predictor of high atherosclerotic burden assessed by coronary computed tomography angiography: the coronary artery disease equivalent revisited. Int J Cardiovasc Imaging (2012) 0.81
Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open (2013) 0.81
Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81
Comparison of treatment outcomes in patients with and without diabetes mellitus attending a multidisciplinary cardiovascular prevention programme (a retrospective analysis of the EUROACTION trial). BMC Cardiovasc Disord (2015) 0.81
Antiplatelet therapy for every diabetic person? Diabetes Care (2011) 0.80
Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care (2010) 0.80
Suitability of antiplatelet therapy in hypertensive patients. J Hum Hypertens (2014) 0.80
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One (2012) 0.79
Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society. Diabetol Metab Syndr (2014) 0.79
Antiplatelet combinations for prevention of atherothrombotic events. Vasc Health Risk Manag (2011) 0.79
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian J Med Res (2013) 0.79
A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs (2015) 0.78
Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther Adv Drug Saf (2012) 0.78
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care (2011) 0.77
Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis (2013) 0.77
Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study. Diabetol Metab Syndr (2015) 0.77
Amelioration of aspirin induced oxidative impairment and apoptotic cell death by a novel antioxidant protein molecule isolated from the herb Phyllanthus niruri. PLoS One (2014) 0.77
High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. Cardiovasc Diabetol (2015) 0.77
Aspirin resistance: Fact or fiction? A point of view. World J Cardiol (2010) 0.76
Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. Can Fam Physician (2013) 0.76
Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes (2014) 0.76
Approach to preventive care in the elderly. Can Fam Physician (2016) 0.75
Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data? Ther Adv Chronic Dis (2011) 0.75
Type 2 diabetes and ASA. Can Fam Physician (2010) 0.75
Review: current evidence shows no overall benefit of aspirin for primary prevention of cardiovascular disease in diabetes. Ann Intern Med (2010) 0.75
Update in new medications for primary care. J Gen Intern Med (2010) 0.75
Time to rethink aspirin in diabetes? BMJ (2009) 0.75
Is diabetes a coronary artery disease equivalent? Can Fam Physician (2013) 0.75
[Aborder les soins préventifs chez les aînés]. Can Fam Physician (2016) 0.75
Aspirin for primary prevention of vascular disease in people with diabetes. BMJ (2009) 0.75
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care (2011) 0.75
Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals (Basel) (2010) 0.75
Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. Curr Diab Rep (2015) 0.75
Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation. Acta Diabetol (2014) 0.75
Possible adverse drug events leading to hospital admission in a Brazilian teaching hospital. Clinics (Sao Paulo) (2014) 0.75
Sex-specific differential in risk of diabetes-related macrovascular outcomes. Curr Diab Rep (2015) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Identifying relevant studies for systematic reviews. BMJ (1994) 12.21
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract (2007) 7.55
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med (2002) 6.53
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68
Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med (2006) 3.60
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA (1992) 2.52
Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation (2004) 1.81
Aspirin for prevention of cardiovascular events. BMJ (2008) 1.49
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart (2004) 1.14
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med (2007) 1.13
AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J (2007) 1.12
Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost (2005) 1.05
Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ (2008) 1.04
Aspirin resistance and diabetes mellitus. Diabetologia (2008) 0.94
Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA (2008) 0.91
Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med (2009) 0.88
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Association of aspirin use with major bleeding in patients with and without diabetes. JAMA (2012) 4.94
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med (2010) 4.40
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med (2007) 4.23
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09
New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol (2007) 3.87
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis (2008) 3.45
Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol (2012) 3.42
Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis (2005) 3.37
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA (2009) 3.35
Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med (2009) 3.14
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89
Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med (2010) 2.88
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J (2007) 2.42
CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med (2008) 2.40
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2014) 2.35
Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31
Haemoglobin targets: we were wrong, time to move on. Lancet (2007) 2.26
Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet (2007) 2.25
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol (2013) 2.22
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2013) 2.21
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet (2005) 2.09
Purging iron from the heart. Br J Haematol (2004) 2.07
Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med (2003) 2.05
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol (2013) 2.04
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 2.04
Multidimensional Prognostic Index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail (2009) 1.83
Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab (2006) 1.81
Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis (2010) 1.81
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int (2004) 1.79
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail (2010) 1.78
Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail (2003) 1.77
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood (2006) 1.76
The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int (2013) 1.75
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood (2012) 1.74
A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis (2007) 1.73
Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab (2010) 1.69
Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care (2002) 1.68
Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med (2007) 1.68
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood (2012) 1.65
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J (2009) 1.63
Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev (2014) 1.63
Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis (2004) 1.62
Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol (2008) 1.61
Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev (2014) 1.61
Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol (2008) 1.59